Improved Recovery from Liver Fibrosis by Crenolanib.

Area of Science:

• Hepatology
• Molecular Biology
• Cell Biology

Background:

• Chronic liver diseases involve excessive extracellular matrix deposition, leading to fibrosis and impaired liver function.
• Hepatic stellate cells (HSCs) are key players in liver fibrogenesis due to their role in extracellular matrix production.

Purpose of the Study:

• To investigate the effect of Crenolanib, a receptor tyrosine kinase (RTK) class III inhibitor, on hepatic stellate cells (HSCs) and liver fibrosis.
• To elucidate the molecular mechanisms by which Crenolanib influences HSC behavior and fibrogenesis.

Main Methods:

• Induction of liver fibrosis in rats using thioacetamide (TAA) for 18 weeks.
• Treatment of fibrotic rats with Crenolanib for two weeks post-TAA administration.
• Analysis of HSC proliferation, endodermal specification, and signaling pathways (p38 MAPK, JNK, IRE1α, WNT) in response to Crenolanib.

Main Results:

• Crenolanib treatment significantly improved recovery from liver fibrosis in TAA-treated rats.
• Inhibition of RTK signaling by Crenolanib hindered HSC proliferation and induced partial endodermal specification.
• Crenolanib treatment activated stress response pathways (IRE1α, JNK) and led to lipid accumulation in HSCs.

Conclusions:

• Crenolanib impedes HSC proliferation and triggers stress responses, initiating developmental processes in HSCs.
• These Crenolanib-induced changes in HSCs may contribute to the observed improvement in liver fibrosis recovery.
• Targeting RTK signaling represents a potential therapeutic strategy for managing liver fibrosis.